Heart surgery is done to correct problems with the heart. More than half a million heart surgeries are done each year in the United States for a variety of heart problems. Heart surgery is used to correct heart problems in children and adults. This article discusses heart surgeries for adults. For more information about heart surgeries for children, see the Diseases and Conditions Index articles on congenital heart defects, holes in the heart, and tetralogy of Fallot.
The most common type of heart surgery for adults is coronary artery bypass grafting (CABG). During CABG, surgeons use healthy arteries or veins taken from another part of the body to bypass (that is, go around) blocked arteries. CABG relieves chest pain and reduces the risk of heart attack.
Infants born with complex congenital heart disease are not only at risk for serious heart-related complications, but also for developing a deadly bowel disease, regardless of the type of surgical intervention they receive for their heart. These are the findings from a study by Nationwide Children's Hospital, and appearing in Pediatric Critical Care Medicine published online May 6 ahead of print.
A trial on shunts used to direct blood flow to the lungs, led by researchers at the University of Michigan's C.S. Mott Children's Hospital, will lead to better outcomes for kids worldwide born with hypoplastic left heart syndrome, the most common severe heart birth defect.
New clinical data presented today at EuroPCR demonstrate positive long-term performance and durability for the CoreValve transcatheter aortic valve replacement system from Medtronic, Inc. Two-year results from the pivotal 18-French CoreValve multicenter prospective study provide important additional evidence supporting wider use of the world's market-leading transcatheter aortic valve.
Eastern Idaho Regional Medical Center (EIRMC), a full-service regional medical center in Idaho Falls, and West Valley Medical Center, a community hospital in Caldwell, will continue to provide in-network medical care to all Medicare Advantage members enrolled in plans offered by Humana, under terms of a renewal agreement announced today.
Congenital heart defects are the most common type of major birth defect in the U.S., affecting about 25,000 babies each year. Now, a new valve being used at the University of Michigan's C.S. Mott Children's Hospital Congenital Heart Center can help patients delay or avoid multiple surgeries.
A joint clinical trial conducted by the University Hospital and the University of Gothenburg, Sweden, found that an element in human blood, fibrinogen, is likely more vital to the blood's clotting ability in connection with heart surgery than previously considered. If
Physician scientists at the Texas Heart Institute at St. Luke's Episcopal Hospital (THI at St. Luke's) are publishing research this week that reveals new insights into how a particular set of human adult stem cells helps repair damaged hearts following a heart attack in laboratory mice.
Physician scientists at the Texas Heart Institute at St. Luke's Episcopal Hospital (THI at St. Luke's) have been awarded a grant of almost $1.5 million by the National Institutes of Health for research into treatments for patients with end-stage heart failure that would combine heart-assist devices and adult stem-cell treatments.
CardiacAssist Inc. announced today that Baptist Hospital East has adopted the company's TandemHeart System.
Researchers at the Texas Heart Institute at St. Luke's Episcopal Hospital (THI at St. Luke's) announced today the results of research which they believe marks a significant advance in understanding how cardiac-specific genes are turned on during the development of the heart in mice embryos.
Genetic tests conducted on blood samples may replace the current biopsies when it comes to checking if immune systems are rejecting new organs of heart transplant patients. The test would be far less invasive and uncomfortable as compared to the biopsies, not to mention more affordable.
Merrimack Pharmaceuticals, Inc. announced today that it will present pre-clinical data on MM-121 and MM-111, the two lead candidates in the company's pipeline of five novel cancer antibodies, at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held April 17 – 21, 2010, in Washington, D.C.
A 7-year-old boy who was brought to the United States to have his congenital heart defect repaired had successful open-heart surgery Thursday at the Children's Center at Sutter Medical Center, Sacramento by pediatric cardiothoracic surgeon Teimour Nasirov, M.D., and assisted by Mohan Reddy, M.D., an internationally renowned pediatric heart surgeon from Lucile Packard Children's Hospital at Stanford.
At 56, Tim Obrenski found himself getting so exhausted that he couldn't even pull weeds from his garden. A visit to the cardiologist uncovered a major blockage in his heart's left main artery, and he was told he needed bypass surgery.
Medtronic, Inc., announced today that it will appeal the $73.5 million jury verdict returned in the U.S. District Court in Delaware deciding that the CoreValve® transcatheter aortic valve system infringes a valid U.S. Andersen patent owned by Edwards Lifesciences.
OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, announced today it has received U.S. Food and Drug Administration (FDA) approval for NBM-200MP, a non-invasive oximetry and low signal oximetry sensor.
AstraZeneca (NYSE: AZN) today announced results of a new analysis of the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study which showed there were fewer deaths in patients with acute coronary syndromes (ACS) who took the investigational oral antiplatelet ticagrelor (BRILINTA™/BRILIQUE™) within seven days prior to having heart bypass surgery (coronary artery bypass graft, CABG) compared to those who took clopidogrel.
Lipitor® (atorvastatin calcium) 80 mg was associated with a significantly reduced risk of major cardiovascular events compared with Lipitor 10 mg among patients with both coronary heart disease (CHD) and chronic kidney disease (CKD) who were obese or had metabolic syndrome. These data, from two sub-analyses of the Treating to New Targets (TNT) trial that were designed and completed following the completion of TNT, were presented today at the 59th Annual Scientific Session of the American College of Cardiology (ACC) in Atlanta, Ga.
MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that study results published in the January 2010 Annals of Thoracic Surgery demonstrated that coronary artery bypass graft (CABG) patients who undergo Endoscopic Vessel Harvesting (EVH) demonstrate similar long-term clinical outcomes as patients who undergo traditional "open" vein harvest (OVH) but have significantly reduced rates of leg infection.
NorthShore University HealthSystem (NorthShore) interventional cardiologist, Ted Feldman, MD, presented data today at the American College of Cardiology annual scientific sessions from the EVEREST II trial (Endovascular Valve Edge-to-Edge REpair STudy) demonstrating the MitraClip, a novel, first-in-class catheter-based device, is a safe and effective alternative to open heart surgery for select patients with mitral regurgitation.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.